Galactosidase

Galactosidase: A Comprehensive Reference Article

1. Identity and Classification

The term galactosidase encompasses two distinct but related digestive enzyme classes: alpha-galactosidase (α-galactosidase) and beta-galactosidase (β-galactosidase), both of which are used as dietary supplements and food enzymes. Though related by their action on galactose-containing substrates, they differ substantially in their substrate specificity, natural sources, mechanisms of action, and areas of application.

Alpha-Galactosidase (α-Galactosidase)

Alpha-galactosidase (EC 3.2.1.22; α-GAL, α-GAL A; systematic name: α-D-galactoside galactohydrolase) is a glycoside hydrolase enzyme that catalyzes the hydrolysis of terminal, non-reducing α-D-galactose residues in α-D-galactosides, including galactooligosaccharides (GOS), galactomannans, and galactolipids. It catalyzes many catabolic processes, including cleavage of glycoproteins, glycolipids, and polysaccharides. In humans, the enzyme is encoded by the GLA and MYORG genes.

Alpha-galactosidase, a member of glycoside hydrolase family 27, catalyzes the removal of a nonreducing terminal α-galactose residue from polysaccharides, glycolipids, and glycopeptides, and is believed to operate via a double displacement retaining reaction mechanism.

The primary commercial source for dietary supplement use is the filamentous fungus Aspergillus niger. The fungal Aspergillus niger aglA gene, originally annotated as an α-galactosidase, actually encodes an enzyme with predominant α-N-acetylgalactosaminidase activity, and this fungal "α-galactosidase" is structurally and functionally most closely related to human α-N-acetylgalactosaminidase (NAGA, historically termed α-galactosidase B), not to human α-galactosidase A (GLA).

Beta-Galactosidase (β-Galactosidase / Lactase)

Beta-galactosidase has the systematic name beta-D-galactoside galactohydrolase (EC 3.2.1.23) — also known as lactase. The enzyme catalyzes the hydrolysis of the β-(1,4)-glycosidic linkage of lactose (β-D-galactosyl-1,4-D-glucoside), resulting in the generation of D-galactose and D-glucose. In the presence of a high concentration of lactose, the enzyme will also act as a transgalactosylase.

Traditionally, the β-galactosidases most widely used in industry were obtained from Aspergillus spp. and Kluyveromyces spp., because these could be readily obtained with acceptable productivities and yields, and products obtained from these organisms are generally recognized as safe (GRAS status) for human consumption.

The β-galactosidases in general use are mainly derived from microbial sources, which include both prokaryotic and eukaryotic organisms, and they can be purified at high yields directly from fungal organisms or produced in recombinant form at high levels in different expression systems. Other commonly used sources include bacteria (e.g., bifidobacteria) and yeasts (e.g., Kluyveromyces lactis).

2. Natural Sources and Occurrence

Natural Sources of Alpha-Galactosidase

Alpha-galactosidases are found in a wide variety of organisms. These include human, animal, plant, fungi, and bacteria. In the supplement industry, Aspergillus niger is the predominant commercial source. A well-known dietary supplement product sold under the trademark Beano was described as an enzyme that reduces or eliminates intestinal gas produced by foods such as beans, broccoli, bran, and other vegetables and grains; this product contains alpha-galactosidase obtained from Aspergillus niger.

Human bodies do not produce meaningful quantities of this enzyme endogenously. Humans lack the enzyme alpha-galactosidase needed to break the bonds between galactose molecules in raffinose family oligosaccharides (RFOs). Raffinose is non-digestible in humans and other monogastric animals who do not possess the α-GAL enzyme to break down RFOs. These oligosaccharides pass undigested through the stomach and small intestine. In the large intestine, they are fermented by bacteria that do possess the α-GAL enzyme, producing short-chain fatty acids (SCFA) such as acetic, propionic, and butyric acids, as well as the flatulence commonly associated with eating beans and other vegetables.

Substrate Foods: Raffinose Family Oligosaccharides

The naturally occurring raffinose family oligosaccharides (RFOs) are composed of α-(1,6)-galactosides linked to a sucrose unity. The most common are raffinose, stachyose (DP4), verbascose (DP5), and ajugose (DP6). RFOs are widely found in seeds, vegetables, legumes, beans, and whole grains. Raffinose, one of the most abundant RFOs, is a trisaccharide composed of galactose, glucose, and fructose, and can be hydrolyzed by α-galactosidase (EC 3.2.1.22) into sucrose and galactose.

These substrates include the naturally occurring disaccharide melibiose (6-O-alpha-D-galactopyranosyl-D-glucose), the trisaccharide raffinose (O-alpha-D-galactopyranosyl-(1-6)-O-alpha-D-glucopyranosyl-(1-2)-beta-D-fructofuranoside), and the tetrasaccharide stachyose.

Raffinose can be found in beans, cabbage, Brussels sprouts, broccoli, asparagus, other vegetables, and whole grains.

Natural Sources of Beta-Galactosidase

Lactose maldigestion occurs when the content of lactase enzyme, also known as β-galactosidase, is reduced in the small bowel mucosa. This reduction, which typically begins early in childhood, affects more than 70% of the world's population, causing abdominal and gut symptoms including pain, diarrhea, bloating, flatulence, and cramping. These symptoms are the consequence of undigested lactose that, after reaching the colon, is fermented to produce acetate, carbon dioxide, hydrogen gas, sulfur compounds, and methane.

Commercial supplement-grade beta-galactosidase is produced predominantly by fermentation of food-safe fungi and yeasts. Aspergillus oryzae is one of the most important fungal sources of β-galactosidase. The β-galactosidase (lacA) produced by A. oryzae has a pH optimum of 4.5, which is appropriate for lactose hydrolysis of acid whey.

3. Common Forms and Preparations

Alpha-galactosidase (α-Gal) is used in dietary supplements to reduce intestinal gases and help complex food digestion. Commercially, it is available in the following forms:

• Tablets (chewable or swallowable): The most widely marketed consumer form, typically measured in Galactosidase Units (GalU).
• Capsules: Capsule forms are directed to be swallowed right before the first bite, or immediately after meals (up to 30 minutes after first bite).
• Liquid drops: An early commercial formulation, as used in the original Beano product.
• Enteric-coated preparations: Encapsulated beta-D-galactosidase (lactase) pellets have been developed and tested in vitro for their enzymatic activity within an environment simulating both gastric and duodenal conditions. These pellets were found to retain enzymatic activity in gastric pH conditions and were found to hydrolyze lactose in human duodenal fluid.

Enzyme activity for alpha-galactosidase is expressed in Galactosidase Units (GalU) or Food Chemical Codex (FCC) units. Beta-galactosidase (lactase) activity is typically expressed in Lactase Units (ALU, FCC LAC, or UI). Lactase products are typically classified into two general categories: low pH optimum (2.5–3.5) lactase for human oral consumption via tablets or capsules; and neutral pH optimum (6.5–7.0) lactase for use as a food additive in milk, cheese, ice cream, and other food products containing lactose or whey.

4. Traditional and Historical Use

Galactosidase enzymes are not traditional herbal or botanical remedies in the classical sense. They are modern microbially-derived enzymes first isolated and characterized in the mid-to-late twentieth century. No pre-modern traditional medicinal use of isolated galactosidase preparations has been documented in the peer-reviewed literature, as the enzyme concept itself predates the dietary supplement era by only decades.

However, the human experience of oligosaccharide-related digestive distress from legumes is ancient and cross-cultural, and various food preparation techniques — soaking, fermenting, and sprouting beans and grains — have been employed across cultures as traditional methods to reduce digestive symptoms. Legumes have sustained human populations for thousands of years, providing essential nutrients in diets worldwide. However, they contain several anti-nutritional factors, including oligosaccharides, phytic acid, tannins, and lectins, which serve protective functions for the plants but can reduce nutrient bioavailability and cause digestive discomfort in humans.

α-Galactosides are heat resistant and are considered anti-nutritional factors. Feeding with such compounds in soybean-based diets results in a reduction in energy utilization, fiber digestion, and nutrient retention. Traditional fermentation practices — such as the production of tempeh and miso from soybeans — effectively engage microbial alpha-galactosidase activity to degrade these anti-nutritional oligosaccharides during processing, even if the enzyme itself was not named or understood.

Isolated alpha-galactosidase as a dietary supplement was commercialized in the early 1990s, beginning with the introduction of Beano. Prior to the commercialization of alpha-galactosidase as a supplement, individuals had the choice of either avoiding offending foods entirely or using a food additive containing alpha-galactosidase as the only active ingredient.

5. Key Constituents and Active Compounds

Alpha-Galactosidase

Alpha-galactosidase (α-Gal) is an enzyme responsible for the hydrolysis of glycolipids and glycoproteins commonly found in dietary sources.

The principal substrates hydrolyzed by alpha-galactosidase in a digestive context are members of the raffinose family oligosaccharides (RFOs): raffinose, stachyose, and verbascose — the primary anti-nutritional factors found in legumes and certain vegetables like broccoli, cauliflower, and Brussels sprouts.

Alpha-galactosidase (E.C. 3.2.1.22) is an exoglycosidase that targets galactooligosaccharides such as raffinose, melibiose, stachyose, and branched polysaccharides like galactomannans and galacto-glucomannans by catalyzing the hydrolysis of α-1,6-linked terminal galactose residues.

The alpha-galactosidase enzyme reacts with the galactopyranose portion of the raffinose, stachyose, and verbascose molecules, but leaves the glucopyranose fructofuranose portion of those molecules intact.

Beta-Galactosidase (Lactase)

The primary substrate of beta-galactosidase is lactose, the disaccharide found in dairy milk. The enzyme catalyzes the hydrolysis of the β-(1,4)-glycosidic linkage of lactose (β-D-galactosyl-1,4-D-glucoside), resulting in the generation of D-galactose and D-glucose.

6. Mechanisms of Action

Catalytic Mechanism of Alpha-Galactosidase

The degradation of macromolecules, including glycopeptides and glycolipids, occurs in the lysosome via catabolic enzymes. Glycosidases cleave the oligosaccharides from glycoproteins and glycolipids into smaller components used by the cell.

The catalytic mechanism of the enzyme has been derived from X-ray crystal structures of each of the four stages of the double displacement reaction mechanism. Asp-170 acts as the nucleophile, and Asp-231 acts as an acid and then a base over the course of the reaction. The ensemble of structures reveals distortion of the ligand into a ¹S₃ skew (or twist) boat conformation in the middle of the reaction cycle.

Chemical modification has indicated the presence of two carboxyl groups, a tryptophan, and a tyrosine at or near the active site of alpha-galactosidase. A proposed mechanism involves an ionizing group with a pKa of 3.5 — a carboxyl group involved in stabilizing a carbonium ion intermediate — and an ionizing group with a pKa of 6.5 that donates a H⁺ ion in catalysis.

In the gastrointestinal context, orally administered microbial alpha-galactosidase acts in the small intestine to pre-hydrolyze RFOs before they pass intact to the colon. By supplementing diets with alpha-galactosidase, the α-(1→6)-glycosidic linkages are broken, giving sucrose and galactose, which may be utilized for providing partial energy and consequently eliminating their negative effects.

Alpha-galactosidase catalyzes specifically the cleaving of glycosidic linkages between α-(1–6)-galactose-residues. Alpha-galactosidase showed the highest efficiency in decomposing GOS (100% of degradation) and led to non-IBS-triggering degradation products.

Additional Biological Activities

Alpha-galactosidase also has the ability to convert human blood group B to blood group O. It catalyzes the hydrolysis of α-galactose residues from the non-reducing end of B-trisaccharides and is capable of reducing the serological activity of B-red blood cells at neutral pH. Furthermore, alpha-galactosidase is able to interrupt the adhesion of pathogens to human buccal epithelium, properties that show great therapeutic potential.

Human alpha-GAL (EC 3.2.1.22) is responsible for the breakdown of α-galactosides in the lysosome. Defects in human α-GAL lead to the development of Fabry disease, a lysosomal storage disorder characterized by the buildup of α-galactosylated substrates in the tissues.

7. Scientific Evidence by Area of Use

7.1 Reduction of Intestinal Gas and Flatulence in Healthy Individuals

This is the best-evidenced application of alpha-galactosidase supplementation. Oral supplementation with alpha-galactosidase obtained from Aspergillus niger (the active ingredient in Beano) has been shown in multiple clinical trials to reduce bloating, flatulence, gas production, and gas-related symptoms associated with intolerance to legumes and other high-fiber, FODMAP-containing foods.

A key early randomized, double-blind, placebo-controlled study by Di Stefano et al. (published in Digestive Diseases and Sciences, 2007) tested the dose-response relationship directly: eight healthy volunteers ingested 300 or 1200 GalU of alpha-galactosidase or placebo during a test meal containing 420 g of cooked beans. Breath hydrogen excretion and occurrence of bloating, abdominal pain, discomfort, flatulence, and diarrhea were measured for 8 hours. The administration of 1200 GalU of alpha-galactosidase induced a significant reduction of both breath hydrogen excretion and severity of flatulence. The 300 GalU dose did not reach statistical significance in this small study. This study was limited by its very small sample size (n=8).

Two clinical trials involving small sample sizes (19 and 8 persons, respectively) showed that the over-the-counter product Beano, which contains alpha-galactosidase, reduced flatus frequency in normal persons following the ingestion of beans.

Evidence characterization: Positive but based on small, short-duration studies. The effect in healthy individuals ingesting specific legume-containing meals is consistent and biologically plausible, but larger confirmatory trials are lacking.

7.2 Irritable Bowel Syndrome (IBS) and FODMAP Sensitivity

The use of alpha-galactosidase as an adjunct to FODMAP management in IBS has been the subject of several trials with mixed results.

A notable positive finding comes from a randomized, double-blind, placebo-controlled crossover trial published in the American Journal of Gastroenterology (2018) by Tuck, Taylor, Gibson et al. at Monash University. This trial investigated whether oral alpha-galactosidase co-ingestion with foods high in GOS and low in other FODMAPs would reduce symptoms in IBS patients. Thirty-one people with IBS were randomized to the order in which they completed a series of 3-day test periods. During each test period, they took either a full-dose, half-dose, or placebo enzyme treatment, and prior to each test period they followed a diet low in FODMAPs and fiber for 3 days, then consumed a diet that was low in all FODMAPs except GOS. Oral alpha-galactosidase taken with high-GOS foods provided a clinically significant reduction in symptoms in GOS-sensitive individuals with IBS, and this strategy was concluded to be translatable into practice as an adjunct therapy to the low FODMAP diet.

A contrasting finding comes from a larger 12-week RCT published in Scandinavian Journal of Gastroenterology (2016): a total of 125 subjects with IBS received alpha-galactosidase (AG) or placebo at meals for 12 weeks, and the authors found no evidence to support the use of AG routinely in IBS patients. An improvement in clinical response at 4-week follow-up may suggest a long-term effect of unknown mechanism, but could also be attributed to non-responder dropout. Gastrointestinal side effects may have been a coincidence in this study, but irritation of the GI tract by AG administration cannot be excluded.

A further negative finding comes from a small crossover pilot study published in Neurogastroenterology & Motility (2021) involving 20 adult IBS patients: all test meals were well tolerated but induced a gradual increase in GI symptom severity. Neither GI symptom ratings over time, nor hydrogen and methane concentrations differed between the days with alpha-galactosidase or placebo. Conclusions stated that the use of alpha-galactosidase together with meals high in oligosaccharides was not superior to placebo in reducing postprandial GI symptoms or the concentration of hydrogen and methane in expired air in IBS. A key limitation of that study was the acknowledged lack of a sample size calculation. The complaint of "too much gas" causing abdominal pain, bloating, distension, and flatulence in IBS is probably of multifactorial origin, where intestinal gas production itself is only one component of the sensation.

Evidence characterization: Mixed. The Tuck/Gibson/Monash trial (2018), which controlled dietary GOS intake specifically, showed a significant benefit in GOS-sensitive IBS patients. The larger longer-duration trial (n=125) did not find benefit for unselected IBS patients treated across all meal types. The evidence suggests benefit may be limited to patients with demonstrable GOS/galactooligosaccharide sensitivity eating identifiable high-GOS foods, rather than all IBS patients broadly.

7.3 Gas-Related Symptoms in Children

A randomized, double-blind, placebo-controlled trial published in PMC (ClinicalTrials.gov: NCT01595932) assessed alpha-galactosidase in the pediatric population. The digestive enzyme decreased the number of days with moderate to severe bloating (p = 0.03) and the proportion of patients with flatulence (p = 0.02). No significant differences were found for abdominal spasms and abdominal distension. No adverse events were reported during treatment. Although larger and longer trials are needed to confirm this result, alpha-galactosidase seems to be a safe, well-tolerated, and effective treatment for gas-related symptoms in the pediatric population.

Evidence characterization: Preliminary. A single small pediatric RCT with positive results; larger trials are needed before firm conclusions can be drawn.

7.4 Lactose Intolerance (Beta-Galactosidase / Lactase)

The use of exogenous beta-galactosidase (lactase) supplements for lactose intolerance is supported by multiple clinical trials across different formulations.

A crossover double-blind placebo-controlled study by Montalto et al. published in the European Journal of Clinical Nutrition (2005) evaluated beta-galactosidase from Kluyveromyces lactis in 30 lactose malabsorbers (11 male and 19 female, mean age 43.3 years). In one arm, the enzyme (3000 UI) was added to milk 10 hours before consumption; in another arm, beta-galactosidase (6000 UI) was added 5 minutes before milk ingestion; and a placebo arm was also tested. The study showed that lactase obtained from K. lactis can represent a valid therapeutic strategy, with objective and subjective efficacy and without side effects, in lactose malabsorbers with intolerance.

A study by Ibba et al. (2014), published in BioMed Research International, assessed beta-galactosidase from Aspergillus oryzae in 96 consecutive patients with lactose malabsorption confirmed by hydrogen breath test, and evaluated effects on hydrogen breath excretion and GI symptoms. The study aimed to assess whether supplementation with a standard oral dose of beta-galactosidase obtained from Aspergillus oryzae affects hydrogen breath excretion and GI symptoms in lactose intolerant patients.

A pellet-form beta-D-galactosidase was assessed in a randomized, double-blind, crossover trial of 8 lactose-intolerant subjects. Results showed a statistically significant increase in plasma glucose levels at 30, 60, 90, and 120 minutes after lactose ingestion, and subjective ratings of the severity of abdominal cramping, belching, flatulence, vomiting, and diarrhea were significantly decreased following ingestion of the lactase pellets and lactose compared with after ingestion of placebo and lactose.

Laboratory assessments have further shown that preparation matters. Both K. lactis and A. oryzae beta-galactosidases were completely inactivated under simulated gastric conditions (pH 2). When the enzymes were subjected to simulated small intestine conditions (pH 7.4), lactose hydrolysis occurred, but at 37°C the percentage was lower than that under optimal temperatures. Under simulated intestinal conditions, the enzyme from K. lactis was more effective on lactose hydrolysis compared to the enzyme from A. oryzae, and it is therefore extremely necessary to use an enteric coating on beta-galactosidase capsules so that this enzyme is released only in the small intestine.

A combined alpha- and beta-galactosidase preparation was evaluated in a pilot open-label study (Di Pierro et al., 2015, Clinical and Experimental Gastroenterology), concluding that a fixed mixture of pure and enteric-coated α- and β-galactosidase is a valid and safe optional treatment to counteract lactose and complex carbohydrate intolerance in subjects who prefer not to avoid offending foods.

Evidence characterization: Moderate. Multiple RCTs support beta-galactosidase (lactase) supplementation for lactose malabsorption and intolerance. Evidence is stronger than for alpha-galactosidase, given the larger body of consistent trials, though most individual studies are small. Formulation (especially enteric coating, source organism, and dose) significantly affects efficacy.

7.5 Anti-Nutritional Factor Reduction in Animal Nutrition

Dietary supplementation of an exogenous enzyme preparation composed mainly of alpha-galactosidase can reduce the negative effects of α-galactosides in soybean meal-based diets. The feed conversion ratio was significantly increased in the low-energy diet group without supplementation of alpha-galactosidase; this negative effect on growth performance was corrected by alpha-galactosidase supplementation. While these data come from poultry studies (not humans), they illustrate the biological potency of the enzyme against dietary RFOs and are relevant to understanding its mechanism in human digestion.

8. Body Systems and Health Areas

• Digestive / Gastrointestinal System: The primary target. More than 20% of the general population suffers from abdominal pain or discomfort caused by intestinal gas and by indigested or partially digested food residuals; alpha-galactosidase is used in dietary supplements to reduce intestinal gases and help complex food digestion.
• Small Intestine: Site of action for both alpha- and beta-galactosidase supplements when taken orally with food. Pre-hydrolysis of RFOs and lactose in the small intestine prevents their fermentation in the colon.
• Lysosomal / Cellular Metabolism (Endogenous α-GAL A): Human alpha-GAL A (EC 3.2.1.22) is responsible for the breakdown of α-galactosides in the lysosome. Defects in human α-GAL lead to the development of Fabry disease, a lysosomal storage disorder characterized by the buildup of α-galactosylated substrates in the tissues. Note: enzyme replacement therapy for Fabry disease (agalsidase alfa and agalsidase beta, pharmaceutical-grade recombinant human alpha-galactosidase A) is a regulated medicinal product and is distinct from over-the-counter digestive supplement preparations.
• Hematological (Research Context): The enzyme can remove the terminal alpha-galactose residue from the erythrocyte surface antigen conferring blood group B specificity, which has potential medical use in transfusion therapy by converting blood group type B to universal donor type O.
• Gut Microbiome: By pre-digesting GOS before colonic fermentation, alpha-galactosidase supplementation reduces the substrate available for fermentation. High-fiber prebiotic fibers such as fructans and galacto-oligosaccharides are known to provide benefits supporting short-chain fatty acid (SCFA) production and digestive health. In-vitro research demonstrates that alpha-galactosidase administration with prebiotic fiber reduces but does not deplete SCFA production, suggesting that use of digestive enzymes with FODMAPs may be more favorable to overall colonic health than avoiding FODMAPs altogether.

9. Dosage Forms and Reported Dosages

Alpha-Galactosidase

Dosages in clinical studies have varied. Specific dosages reported in source-verified studies include:

• Eight healthy volunteers received 300 or 1200 GalU of alpha-galactosidase or placebo during a test meal containing 420 g of cooked beans, with significant reductions in gas at 1200 GalU but not 300 GalU.
• A 3-month IBS intervention used daily 3 × 3 capsules of alpha-galactosidase enzyme (400 GalU/capsule) or matching placebo.
• A reported recommended dosage range cited for alpha-galactosidase is 260–3000 FCC (Food Chemical Codex) units per day.
• Consumer product labeling directs swallowing 1 capsule right before the first bite, or immediately after meals (up to 30 minutes after first bite).

Beta-Galactosidase (Lactase)

• In one study, 3000 UI of beta-galactosidase from K. lactis was added to 400 ml of milk 10 hours before consumption, while 6000 UI was added 5 minutes before milk ingestion, and both were compared to placebo.
• In an enteric-coated pellet trial, subjects were given one capsule containing 100 u/ml beta-galactosidase.
• Lactase products are broadly categorized into low pH-optimum formulas for oral tablet/capsule use and neutral pH-optimum formulas for use as dairy food additives.

10. Safety Considerations and Interactions

General Safety Profile

Marketed enzyme-containing dietary supplements must be produced in accordance with the Food and Drug Administration (FDA) regulations for Current Good Manufacturing Practice (cGMPs).

The safety of beta-galactosidase from multiple source organisms has been formally evaluated by the European Food Safety Authority (EFSA). Systemic toxicity of beta-galactosidase from A. oryzae strain GL 470 was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no-observed adverse effect level (NOAEL) of 7,000 mg TOS/kg bw per day — the highest dose tested — which when compared with the estimated dietary exposure, results in a wide margin of exposure.

For alpha-galactosidase as a consumer supplement, the safety profile is generally considered favorable in the scientific literature: no adverse events were reported during treatment in the pediatric RCT. No adverse events were reported during treatment in the IBS pilot study; alpha-galactosidase seems to be a safe and well-tolerated treatment for gas-related symptoms.

Allergic Reactions

Hypersensitivity is uncommon but possible, particularly for those allergic to mold or fungi, since most commercial alpha-galactosidase is derived from Aspergillus niger. Symptoms might include rash, itching, or in rare cases, more severe allergic responses.

Regarding beta-galactosidase, cases of occupational allergy (rhinitis, conjunctivitis, sneezing, cough, shortness of breath, and pruritus) following exposure to beta-galactosidases by inhalation or by skin and mucous membrane contact have been reported. However, several studies have shown that adults with occupational asthma to a food enzyme may be able to ingest the corresponding respiratory allergens without acquiring clinical symptoms of food allergy.

Contraindications

Side effects are rare, but those with galactosemia or allergies to the source organisms should avoid galactosidase supplements. Galactosemia is a rare genetic metabolic disorder in which affected individuals cannot properly metabolize galactose; the release of free galactose from enzyme hydrolysis of oligosaccharides and lactose could pose risk in this population.

Potential Interaction: Agalsidase Beta (Pharmaceutical)

Note that interactions documented in drug databases pertain specifically to the pharmaceutical enzyme replacement therapy form (agalsidase beta, used for Fabry disease), not to the dietary supplement form. The therapeutic efficacy of agalsidase beta (pharmaceutical) can be decreased when used in combination with amiodarone, chloroquine, or gentamicin. These interactions are relevant only to the pharmaceutical enzyme replacement therapy product, not to OTC digestive galactosidase supplements.

Interactions with Prescription Medications

Drug interactions with the dietary supplement form of alpha-galactosidase are not generally expected, though formal pharmacokinetic interaction data in humans are limited. One study concluded that alpha-D-galactosidase does not modify the oral pharmacokinetics of trimebutine, rendering co-use suitable for commercial purposes in indicated bowel conditions.

Prebiotic Effects and Microbiome Considerations

Because galacto-oligosaccharides serve as prebiotic substrates for beneficial gut bacteria, their complete pre-digestion by exogenous alpha-galactosidase may theoretically reduce prebiotic delivery to the colon. In-vitro research suggests that alpha-galactosidase administration with prebiotic fiber reduces but does not deplete SCFA production, suggesting that enzyme use with FODMAPs may be more favorable to overall colonic health than avoiding FODMAPs altogether. Formal long-term human studies specifically assessing microbiome composition changes following regular alpha-galactosidase supplementation are lacking.

Mild Adverse Effects

Rarely, some users may notice mild stomach upset, loose stools, or nausea. These effects are typically short-lived and resolve after adjusting the dose or frequency. In one 12-week IBS trial, gastrointestinal side effects were noted, though whether these were attributable to the enzyme or were coincidental could not be definitively excluded.

11. Quality Control and Regulatory Status

Alpha-galactosidase is an enzyme responsible for the hydrolysis of glycolipids and glycoproteins commonly found in dietary sources, used in dietary supplements to reduce intestinal gases and help complex food digestion; marketed enzyme-containing dietary supplements must be produced in accordance with the FDA regulations for Current Good Manufacturing Practice (cGMPs).

Enzyme activity quantification in finished products requires validated analytical methods. A spectrophotometric enzymatic assay for alpha-galactosidase (α-Gal) activity quantification in dietary supplements has been developed and validated. The European Food Safety Authority (EFSA) has conducted formal safety evaluations of beta-galactosidase preparations from Aspergillus oryzae, Kluyveromyces lactis, and Bacillus sp. under the EU food enzyme regulatory framework (Regulation EC No. 1332/2008), providing the most rigorous publicly available toxicological evaluations for these enzyme sources.

References

• Fabris E, Bulfoni M, Nencioni A, Nencioni E. Intra-Laboratory Validation of Alpha-Galactosidase Activity Measurement in Dietary Supplements. Molecules. 2021;26(6):1566. PMC8000382.
• Guce AI et al. Catalytic Mechanism of Human α-Galactosidase. Journal of Biological Chemistry. 2010;285(6):3625–3632. PMC2823503.
• Guce AI et al. Catalytic mechanism of human alpha-galactosidase. PubMed PMID: 19940122.
• Alpha-Galactosidase — ScienceDirect Topics Overview.
• α-Galactosidase — Wikipedia. (For structural/classification facts cross-referenced with primary sources.)
• Di Stefano M et al. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Digestive Diseases and Sciences. 2007;52(1):78–83. PMID: 17151807.
• Hillilä M et al. Does oral α-galactosidase relieve irritable bowel symptoms? Scandinavian Journal of Gastroenterology. 2016;51(1):16–21. PMID: 26133538.
• Böhn L et al. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in IBS patients. Neurogastroenterology & Motility. 2021. PMID: 33619835.
• Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing symptoms in IBS with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment. American Journal of Gastroenterology. 2018;113(1):124–134.
• Miele E et al. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo-controlled trial. PMC3849317.
• Montalto M et al. Effect of exogenous β-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study. European Journal of Clinical Nutrition. 2005.
• Barillas C, Solomons NW. Treatment of lactose intolerance with exogenous beta-D-galactosidase in pellet form. PMID: 9725505.
• Ibba I et al. Effects of Exogenous Lactase Administration on Hydrogen Breath Excretion and Intestinal Symptoms in Patients Presenting Lactose Malabsorption and Intolerance. BioMed Research International. 2014. PMC4055537.
• Di Pierro F et al. A pilot trial on subjects with lactose and/or oligosaccharides intolerance treated with a fixed mixture of pure and enteric-coated α- and β-galactosidase. Clinical and Experimental Gastroenterology. 2015;8:95–100. PMC4340330.
• Amer SA et al. Effect of dietary supplementation of alpha-galactosidase on growth performance, ileal digestibility, intestinal morphology, and biochemical parameters in broiler chickens. PMC7238633.
• Enzymatic degradation of FODMAPs via application of β-fructofuranosidases and α-galactosidases — ScienceDirect.
• EFSA Panel. Safety evaluation of the food enzyme beta-galactosidase from Bacillus sp. (strain M3-1). EFSA Journal. 2019. PMC7008825.
• EFSA. Safety evaluation of the food enzyme β-galactosidase from Kluyveromyces lactis strain AE-KL. EFSA Journal. 2022.
• EFSA. Safety evaluation of the food enzyme β-galactosidase from Aspergillus oryzae strain AE-LA. EFSA, 2022.
• EFSA. Safety evaluation of the food enzyme β-galactosidase from Aspergillus oryzae strain GL 470. EFSA, 2022.
• Recombinant Aspergillus β-galactosidases as a robust glycomic and biotechnological tool. PMC3973953.
• Optimization and partial purification of beta-galactosidase production by Aspergillus niger. PMC6557963.
• ClinicalTrials.gov NCT01243853: Alpha-galactosidase Enzyme and Irritable Bowel Syndrome.
• DailyMed (NIH): Alpha Galactosidase — Product Label Information.
• Cleveland Clinic: Alpha-Galactosidase Capsules or Tablets — Drug/Supplement Information.
• Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease. Gastroenterology. 2020.